Émilie ROYERE
MBA
-
General Director of the competitiveness cluster Eurobiomed
Eurobiomed
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
I participated in 2004 in the creation of the Bioméditerranée cluster foreshadowing the Eurobiomed competitiveness cluster, which is currently the catalyst of the health sector in the Provence-Alpes-Côte d’Azur and Languedoc-Roussillon regions with 400 companies, 8 Universities, 400 research centres, 4 University Hospitals Centres and one Interregional Clinical Research Organization.
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential. Marseille Immunopole is a perfect illustration of this approach and we are very proud of the magnitude taken today by this new operation initiated in 2013. Eurobiomed still remains very involved, animating the community and participating in the driving force that allows the creation of start-ups and the development of industrials and service companies in MI and the implementation of ambitious partnerships in France and internationally on these issues.
#ecosystèmeHave a look on our testimonies
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.
Christian CHABANNON
AMU, IPC, AP-HM, Inserm
The Pioneer Project draws on the collaborative environment of Marseille Immunopôle, which brings together clinicians, academics and industry players committed to the benefit of patients
Laurent GREILLIER
AP-HM, AMU
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”
Pierre d’EPENOUX
Imcheck Therapeutics
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
Jean-Paul BORG
AMU, IPC, CRCM
your commitment to MI